Esophageal Cancer (EC) is one of most common cancers worldwide. China, in particular, accounts for more than half of the new cases globally each year. Radiotherapy (RT) is one of the important treatment methods of EC, including preoperative and postoperative RT, RT concurrent with chemotherapy (CRT) for locally advanced EC, definitive CRT for inoperable EC, and palliative RT for patients with distant metastatic disease . So far, preoperative CRT followed with surgery is considered as the standard treatment for patients with locally advanced EC. However, even with the standard treatment, the overall survival rate at 5-year is only about 40%. How to substantially improve the efficacy of EC remains unaddressed in cancer research. Current solutions include: 1. Minimally invasive esophagectomy combined with neoadjuvant chemoradiotherapy; 2. Radical chemoradiotherapy using advanced RT techniques, including intensity-modulated RT (IMRT) and volumetric modulated arc therapy (VMAT), etc.al. 3. Systemic therapy using new drugs such as novel chemotherapy regimens, immune check-point inhibitors (ICIs), targeted drugs, anti-angiogenesis, etc.al.
In this Research Topic, we aim to introduce the latest progress in the basic research and Radiotherapy treatments of esophageal cancer. We welcome submissions of Original Research, Review, and Mini-review . The subtopics of interest include but are not limited to: clinical trial, randomized controlled trial, basic research, and translational research, etc.al.
We welcome submissions of Review, Mini-Review and Original Research articles covering, but not limited to, the following two aspects of topics:
1. New radiotherapy techniques (such as proton and heavy ion) for Esophageal Cancer (EC);
2. New surgery techniques combined with Radiotherapy (RT) for Esophageal Cancer (EC);
3. Radiotherapy (RT) combined with new drugs for Esophageal Cancer (EC), such as novel chemotherapy regimens, immune check-point inhibitors (ICIs), targeted drugs, anti-angiogenesis, etc.al (specifically studies focusing on the phase III multicentre clinical studies and real-world studies of ICIs);
4. Development of Radiotherapy (RT) combined with surgery and medical treatment for recurrent and refractory for Esophageal Cancer (EC);
5. Research of Radiotherapy (RT) related epigenetics, proteomics, genomics and tumor microenvironment for Esophageal Cancer (EC).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Esophageal Cancer (EC) is one of most common cancers worldwide. China, in particular, accounts for more than half of the new cases globally each year. Radiotherapy (RT) is one of the important treatment methods of EC, including preoperative and postoperative RT, RT concurrent with chemotherapy (CRT) for locally advanced EC, definitive CRT for inoperable EC, and palliative RT for patients with distant metastatic disease . So far, preoperative CRT followed with surgery is considered as the standard treatment for patients with locally advanced EC. However, even with the standard treatment, the overall survival rate at 5-year is only about 40%. How to substantially improve the efficacy of EC remains unaddressed in cancer research. Current solutions include: 1. Minimally invasive esophagectomy combined with neoadjuvant chemoradiotherapy; 2. Radical chemoradiotherapy using advanced RT techniques, including intensity-modulated RT (IMRT) and volumetric modulated arc therapy (VMAT), etc.al. 3. Systemic therapy using new drugs such as novel chemotherapy regimens, immune check-point inhibitors (ICIs), targeted drugs, anti-angiogenesis, etc.al.
In this Research Topic, we aim to introduce the latest progress in the basic research and Radiotherapy treatments of esophageal cancer. We welcome submissions of Original Research, Review, and Mini-review . The subtopics of interest include but are not limited to: clinical trial, randomized controlled trial, basic research, and translational research, etc.al.
We welcome submissions of Review, Mini-Review and Original Research articles covering, but not limited to, the following two aspects of topics:
1. New radiotherapy techniques (such as proton and heavy ion) for Esophageal Cancer (EC);
2. New surgery techniques combined with Radiotherapy (RT) for Esophageal Cancer (EC);
3. Radiotherapy (RT) combined with new drugs for Esophageal Cancer (EC), such as novel chemotherapy regimens, immune check-point inhibitors (ICIs), targeted drugs, anti-angiogenesis, etc.al (specifically studies focusing on the phase III multicentre clinical studies and real-world studies of ICIs);
4. Development of Radiotherapy (RT) combined with surgery and medical treatment for recurrent and refractory for Esophageal Cancer (EC);
5. Research of Radiotherapy (RT) related epigenetics, proteomics, genomics and tumor microenvironment for Esophageal Cancer (EC).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
